# US 2024/0255880 A1 · Serpina1 sirnas: compositions of matter and methods of treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0255880 A1
- Document ID: US20240255880A1
- Status: Published application
- Kind: A1
- Application number: 18/239,189
- Filed: 2023-08-29
- Published: 2024-08-01
- Earliest claimed: 2011-06-23
- Assignees: Alnylam Pharmaceuticals, Inc.
- Applicants: Alnylam Pharmaceuticals, Inc.
- Inventors: Alfica Sehgal; David Bumcrot; Brian Bettencourt
- Web page: https://patentgrep.com/patent/US20240255880A1

## CPC

- G03G 15/556: {for toner consumption, e.g. pixel counting, toner coverage detection or toner density measurement}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- G03G 15/0853: {the concentration being measured by magnetic means}
- G03G 15/086: {the level being measured by electro-magnetic means}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- C12N 2310/3521: Methyl
- G03G 2215/0888: Arrangements for detecting toner level or concentration in the developing device
- G03G: ELECTROGRAPHY; ELECTROPHOTOGRAPHY; MAGNETOGRAPHY
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpina1 gene, and methods of using such dsRNA compositions to inhibit expression of Serpina1.

## Claims

### Claim 1

A Serpina-1 inhibiting double stranded ribonucleic acid (dsRNA) comprising:
i. a sense strand molecule which is 19-23 nucleotides in length comprising at least 19 contiguous nucleotides of SEQ ID NO:62, said sense strand comprising at least 10 nucleotides comprising a 2′-O-methyl modification;
ii. a separate antisense strand molecule which is 19-23 nucleotides in length comprising at least 19 contiguous nucleotides of SEQ ID NO: 106, said antisense strand comprising at least 3 nucleotides comprising a 2′O-methyl modification; and
iii. at least 19 of the nucleotides in each strand comprise a nucleotide modification; and
wherein the sense strand and antisense strand are two separate molecules.

### Claim 2 (depends on 1)

The dsRNA of claim 1, wherein all of the nucleotides in said antisense strand comprise a nucleotide modification.

### Claim 3 (depends on 1)

The dsRNA of claim 1, wherein said nucleotide modifications are selected from the group consisting of: 2′-deoxy-2′-fluoro modified nucleotide modification, a 2′-deoxy nucleotide modification, a locked nucleotide modification, an abasic nucleotide modification, 2′-amino nucleotide modification, 2′-alkyl-nucleotide modification, morpholino nucleotide modification, a phosphoramidate modification, and a non-natural base comprising nucleotide modification.

### Claim 4 (depends on 1)

The dsRNA of claim 1, wherein said sense strand comprises at least one phosphorothioate linkage.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The dsRNA of claim 1, wherein said antisense strand comprises at least one phosphorothioate linkage.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The dsRNA of claim 1, wherein said dsRNA comprises a ligand.

### Claim 9 (depends on 8)

The dsRNA of claim 8, wherein said ligand comprises at least one carbohydrate conjugate.

### Claim 10 (depends on 8)

The dsRNA of claim 8, wherein said ligand is attached to the 5′ end of said sense strand.

### Claim 11 (depends on 1)

The dsRNA of claim 1, wherein said sense strand comprises at least one inverted nucleotide linkage.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The dsRNA of claim 1, wherein said sense strand comprises a 2′-O-methyl nucleotide modification at positions 1, 3, 4, 5, 9, 11, 13, 14, 15, and 18 of the 19 contiguous nucleotides of SEQ ID NO 62.

### Claim 14 (depends on 1)

The dsRNA of claim 1, wherein said antisense strand comprises a 2′-O-methyl nucleotide modification at position 8 of the 19 contiguous nucleotides of SEQ ID NO:106.

### Claim 15 (depends on 1)

The dsRNA of claim 1, wherein all uridine nucleotides of the sense strand comprise a 2′-O-methyl modification.

### Claim 16 (depends on 1)

The dsRNA of claim 1, wherein all adenine nucleotides of the sense strand comprise a 2′-O-methyl modification.

### Claim 17 (depends on 1)

The dsRNA of claim 1, wherein said antisense strand comprises at least one cytosine nucleotide comprising a 2′-O-methyl modification.

### Claim 18

(canceled)

### Claim 19

A Serpina-1 inhibiting double stranded ribonucleic acid (dsRNA) comprising:
i. a sense strand molecule which is 19-23 nucleotides in length comprising:
A. at least 19 contiguous nucleotides of SEQ ID NO:62;
B. three phosphorothioate linkages;
C. a ligand attached to the 5′ end wherein said ligand comprises at least one carbohydrate conjugate;
D. at least one inverted base;
E. all of the nucleotides comprise a nucleotide modification;
F. at least 10 nucleotides comprising a 2′-O-methyl modification; and
ii. a separate antisense strand molecule which is 19-23 nucleotides in length comprising:
A. at least 19 contiguous nucleotides of SEQ ID NO: 106;
B. three phosphorothioate linkages;
C. all of the nucleotides comprise a nucleotide modification;
D. at least 3 nucleotides comprising a 2′-O-methyl modification; and
wherein the sense strand and antisense strand are two separate molecules.

### Claim 20 (depends on 19)

The dsRNA of claim 19, wherein said antisense strand comprises at least one cytosine nucleotide comprising a 2′-O-methyl modification.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

A method of inhibiting Serpina1 expression in a cell, the method comprising: (a) introducing into the cell the dsRNA of claim 1; and (b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of a Serpina1 gene, thereby inhibiting expression of the Serpina1 gene in the cell.
